Home » VERTEX TO CURTAIL FUNDING OF TWO DRUGS
VERTEX TO CURTAIL FUNDING OF TWO DRUGS
Biotech firm Vertex Pharmaceuticals Inc. said Tuesday that it plans to sharply reduce its investment in two clinical-stage treatments -- one aimed at improving hepatitis C therapies and another at psoriasis -- to marshall its funds for more commercially promising drugs. Vertex said it will instead concentrate its resources in 2006 on mid-stage trials of its direct hepatitis C drug and its rheumatoid arthritis therapy. In addition, the company plans to start clinical studies for a drug to treat cystic fibrosis.
Forbes (http://www.forbes.com/technology/feeds/ap/2005/10/04/ap2260288.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May